FDA Approves First-in-Class Drug for Severe Asthma

The US Food and Drug Administration has granted early approval to Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of patients age 12 years and older with severe asthma.
FDA Approvals

source https://www.medscape.com/viewarticle/965139?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost